Genetic Testing Pioneer DnaNudge Signs Key Agreement With Spain’s Largest Clinical Group Quirónprevención
7.9.2021 09:00:00 EEST | Business Wire | Press release
Consumer genetics testing and medical diagnostics pioneer DnaNudge today announces that it has signed a new major distributor agreement that will speed the commercial roll-out of its breakthrough rapid genetic testing solutions across Spain.
The new strategic partnership with Madrid-based Quirónprevención, grants the experienced distributor the exclusive rights to market and sell DnaNudge’s Nutrition Service, the upcoming DnaNudge Skincare service, and the first ever sample-to-result RT-PCR COVID-19 test (‘CovidNudge’). Quirónprevención is part of Quirónsalud – the leading hospital group in Spain and one of the world’s largest hospital groups. This new distributor signing is part of a significant ramp-up in the next phase of DnaNudge’s commercial growth, following its successful completion of a $60 million Series A investment round led by investment company Ventura Capital. DnaNudge’s first major fund-raising round also included participation from the world’s largest independent wealth manager Bank Julius Baer.
DnaNudge’s portable, clinical-grade point-of-care testing platform – which delivers accurate results in just over an hour, without the need for a laboratory or any manual sample pre-processing – is generating intense commercial interest from healthcare providers, private organisations and government bodies worldwide. DnaNudge has entered into a number of significant wholesale supply agreements, delivering its COVID-19 rapid, lab-free test at scale to major international healthcare companies.
Commenting on the new partnership, Regius (Royal) Professor Chris Toumazou FRS, FREng, FMedSci, CEO and co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London said: “We are delighted to have signed this new strategic agreement with Quirón Prevención, S.L that will dramatically speed availability of our products for businesses and consumers across Spain. Our breakthrough rapid, lab-free COVID-19 test provides a highly accurate and easy-to-use solution that offers crucial reassurance and protection for people and businesses as key sectors of our societies and economies begin to build back. From public and private healthcare providers to corporate customers and the vital travel industry, the global market demand for our solutions is extremely high, and we look forward to announcing further partnerships in the very near future that will enable us to serve this interest worldwide.”
The CE-marked CovidNudge test was adapted in record time last Spring from DnaNudge’s on-the-spot consumer DNA testing service, available at its flagship store in London’s Covent Garden. DnaNudge offers the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier and more personalised choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profiles to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The company will shortly be extending its consumer genetics services into personalised skincare shopping. In July, DnaNudge was named the winner of the prestigious Royal Academy of Engineering’s MacRobert Award, the UK's longest-running national prize for engineering innovation.
Capable of a high level of multiplexing, with 72 different testing wells available on a single testing cartridge, the transformative DnaNudge testing platform offers the ability to test simultaneously for all known SARS-CoV-2 virus variants, FluA, FluB, respiratory syncytial virus (RSV), plus markers indicating genetic risk for key health conditions – all on the same test cartridge, from sample direct to result.
Ends---
About DnaNudge (http://www.dnanudge.com)
DnaNudge is the developer of the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profile to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The service has been developed by world-renowned biomedical engineer Regius Professor Chris Toumazou FRS and published geneticist Dr Maria Karvela.
This ground-breaking DNA testing service created to address an epidemic – obesity and Type 2 diabetes – has been successfully adapted for the fight against a pandemic, with the development of the rapid, lab-free CovidNudge RT-PCR test. CovidNudge can accurately detect COVID-19 and other viruses in just over an hour, without the need for a laboratory, and is in use in hospitals around the world.
About Quirónprevención
Quirónprevención is the occupational health and safety consulting company part of the Fresenius Group. We take care of our customer's companies ensuring safety in their work centers and the health of the people who work in them. We are currently the leading company in our sector nationally as well internationally, with more than 5 thousand professionals taking care of 190 thousand companies and 4 million workers.
Due to this implantation, Quirónprevención is able to offer a global service, standardizing and adapting the policies of our customers in each of the countries where they operate. Innovation is another mainstay of our corporate identity and the way we work. We are aware that we live in a society that changes and updates at a dizzying speed, in which new generations and new professional profiles are being incorporated. Those we have to reach in order to continue doing our job. This requires a constant renewal and recycling, new format development and new innovative solutions that help us integrate health and safety culture at every level of the company, making attractive content.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005275/en/
Contact information
PRESS CONTACT for DnaNudge:
Nicky Denovan
EvokedSet PR
Email: nicky@evokedset.com
Phone: +44 (0) 118 328 2782
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 16:30:00 EEST | Press release
ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential challenges facing modern data systems, as AI reshapes the demands placed on all data-intensive workloads. “At ClickHouse, we are interested in finding new and inno
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 16:30:00 EEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 16:00:00 EEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 15:30:00 EEST | Press release
Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 760 million users around the world, serving more than 350 banking clients in 21 different countries, including more than 100 of the largest bank
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 15:16:00 EEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom